Research

A Fox Chase Cancer Center study using young, middle‑aged and geriatric mice suggests melanoma incidence and mortality are strongly age‑dependent and that age‑related immune changes can promote aggressive melanoma spread, particularly in middle age.

Researchers at Fox Chase Cancer Center have demonstrated that extending postoperative blood clot prevention medication for patients undergoing DIEP flap breast reconstruction significantly reduces the risk of venous thromboembolism (VTE), a potentially life-threatening complication.

Researchers at Fox Chase Cancer Center have uncovered a new mechanism by which the body’s immune system responds to viral infections, a finding that can potentially be harnessed to attack cancer.

Researchers at Fox Chase Cancer Center were part of an international team that found a steep rise in kidney cancer cases will be driven largely by preventable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension.

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.

A pilot study from Fox Chase Cancer Center, presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, offers patients and physicians new options. Researchers found that using CT adaptive stereotactic body radiation therapy (CTA-SBRT) can make repeat radiation not only possible, but safe.

Using a novel method to analyze tumor growth rates, researchers at Fox Chase Cancer Center have provided the most in-depth assessment to date of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging, which measures the extent of cancer spread in the body. The newly published study offers new insight into how tumors progress in the time between diagnosis and surgery.